Table 1.
Pharmacokinetic profile
| Simvastatin | |
|---|---|
| Absorption | 61%–85% (not altered by food) |
| First pass extraction | >95% of administered dose |
| Bioavailability | <5% |
| Metabolism | CYP4503A4 |
| Tmax | 2.5–4 h |
| Half-life | 2 h |
| Elimination | Feces (58%); urine (13%) |
| Protein binding | 94%–98% |
| Drug–drug interaction | Gemfibrozil, Cyclosporine, Warfarin, Digoxin |
|
| |
| Fenofibrate | |
|
| |
| Absorption | Better in fed state for micronized particles (160 mg) Independent for nanoparticles (145 mg) |
| Bioavailability | 60% |
| Metabolism | Hepatic (glucuronidation) |
| Tmax | 3.5 h |
| Half-life | 19–27 h |
| Elimination | Feces (25%); urine (60%) |
| Protein binding | 99% |
| Drug–drug interaction | Cyclosporine, Pravastatin, Simvastatin (?),Warfarin, Erythromycin |